{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:36:57Z","timestamp":1766086617133,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.biopha.2010.03.003","type":"journal-article","created":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T04:51:11Z","timestamp":1272689471000},"page":"550-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance"],"prefix":"10.1016","volume":"64","author":[{"given":"Qiang","family":"Zuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinzhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongcheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2010.03.003_bib1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/BF01907986","article-title":"Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique","volume":"38","author":"Wang","year":"1993","journal-title":"Jpn J Hum Genet"},{"key":"10.1016\/j.biopha.2010.03.003_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2003.10.038","article-title":"Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy","volume":"59","author":"Chua","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.biopha.2010.03.003_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1471-2407-9-112","article-title":"Cetuximab in combination with irinotecan\/5-fluorouracil\/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I\/II study","volume":"9","author":"Raoul","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2010.03.003_bib4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1592\/phco.28.6.742","article-title":"Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer","volume":"28","author":"Jean","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopha.2010.03.003_bib5","article-title":"KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?","author":"Hebbar","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.biopha.2010.03.003_bib6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2010.03.003_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrclinonc.2009.111","article-title":"Implications for KRAS status and EGFR-targeted therapies in metastatic CRC","volume":"6","author":"Normanno","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.biopha.2010.03.003_bib8","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1200\/JCO.2005.02.147","article-title":"Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2010.03.003_bib9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2010.03.003_bib10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl. 4","key":"10.1016\/j.biopha.2010.03.003_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdp126","article-title":"Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biopha.2010.03.003_bib12","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1200\/JCO.1993.11.10.1873","article-title":"Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer","volume":"11","author":"Dassonville","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2010.03.003_bib13","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X","article-title":"Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck","volume":"78","author":"Rubin Grandis","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2010.03.003_bib14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.ijrobp.2003.07.010","article-title":"Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy","volume":"58","author":"Ang","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.biopha.2010.03.003_bib15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/jnci\/90.11.824","article-title":"Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival","volume":"90","author":"Rubin Grandis","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.biopha.2010.03.003_bib16","doi-asserted-by":"crossref","first-page":"896407","DOI":"10.1155\/2009\/896407","article-title":"Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors","volume":"2009","author":"Egloff","year":"2009","journal-title":"J Oncol"},{"key":"10.1016\/j.biopha.2010.03.003_bib17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hed.10307","article-title":"Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study","volume":"25","author":"Ma","year":"2003","journal-title":"Head Neck"},{"key":"10.1016\/j.biopha.2010.03.003_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1590\/S1516-31801999000300004","article-title":"Genetic alterations in Ki-ras and Ha-ras genes in juvenile nasopharyngeal angiofibromas and head and neck cancer","volume":"117","author":"Coutinho","year":"1999","journal-title":"Sao Paulo Med J"},{"key":"10.1016\/j.biopha.2010.03.003_bib19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2174\/138945009789577891","article-title":"Anti-EGFR therapy in colorectal cancer: how to choose the right patient","volume":"10","author":"Meriggi","year":"2009","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.biopha.2010.03.003_bib20","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/sj.bjc.6604848","article-title":"Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant","volume":"100","author":"Molinari","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2010.03.003_bib21","first-page":"731","article-title":"PTEN expression controls cellular response to cetuximab by mediating PI3K\/AKT and RAS\/RAF\/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells","volume":"21","author":"Bouali","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1016\/j.biopha.2010.03.003_bib22","first-page":"1964","article-title":"Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line","volume":"61","author":"Urasaki","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2010.03.003_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1008089512856","article-title":"Cytokine-mediated reversal of multidrug resistance","volume":"27","author":"Stein","year":"1998","journal-title":"Cytotechnology"},{"key":"10.1016\/j.biopha.2010.03.003_bib24","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2010.03.003_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1677\/erc.1.00799","article-title":"Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells","volume":"11","author":"Jones","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.biopha.2010.03.003_bib26","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.bjc.6602559","article-title":"Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)","volume":"92","author":"Kokubo","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2010.03.003_bib27","first-page":"4340","article-title":"Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3\u2032-kinase\/Akt pathway signaling","volume":"9","author":"She","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2010.03.003_bib28","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1158\/0008-5472.CAN-06-0743","article-title":"Akt signaling and cancer: surviving but not moving on","volume":"66","author":"Toker","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2010.03.003_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.biopha.2010.03.003_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2010.03.003_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.bjc.6602926","article-title":"PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer","volume":"94","author":"Fujita","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2010.03.003_bib32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2010.03.003_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2007.10.004","article-title":"PI3 kinase activation and response to trastuzumab therapy: what's new with herceptin resistance?","volume":"12","author":"Park","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2010.03.003_bib34","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/sj.bjc.6604009","article-title":"PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients","volume":"97","author":"Frattini","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2010.03.003_bib35","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.1158\/0008-5472.CAN-04-4392","article-title":"Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2010.03.003_bib36","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1158\/0008-5472.CAN-06-0419","article-title":"Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo","volume":"66","author":"Wendel","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2010.03.003_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/1078-0432.CCR-06-1992","article-title":"PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors","volume":"13","author":"Mellinghoff","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2010.03.003_bib38","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","article-title":"Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency","volume":"13","author":"Lu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2010.03.003_bib39","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12032-008-9124-5","article-title":"PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival","volume":"26","author":"Chou","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.biopha.2010.03.003_bib40","first-page":"4682","article-title":"Ras oncogenes in human cancer: a review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2010.03.003_bib41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<14::AID-AJMG5>3.0.CO;2-4","article-title":"Ras as a therapeutic target in neurofibromatosis type 1","volume":"89","author":"Weiss","year":"1999","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.biopha.2010.03.003_bib42","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","article-title":"The EGF receptor family as targets for cancer therapy","volume":"19","author":"Mendelsohn","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2010.03.003_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/excr.2000.5130","article-title":"PTEN: life as a tumor suppressor","volume":"264","author":"Simpson","year":"2001","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.biopha.2010.03.003_bib44","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1126\/science.286.5445.1741","article-title":"Phosphorylation and regulation of Raf by Akt (protein kinase B)","volume":"286","author":"Zimmermann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.biopha.2010.03.003_bib45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/418244a","article-title":"RNA interference","volume":"418","author":"Hannon","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2010.03.003_bib46","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/gut.46.5.645","article-title":"Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma","volume":"46","author":"Sarela","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2010.03.003_bib47","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/he.2000.6496","article-title":"Survivin promotes cell proliferation in human hepatocellular carcinoma","volume":"31","author":"Ito","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2010.03.003_bib48","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1021\/bi001603q","article-title":"An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7","volume":"40","author":"Shin","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2010.03.003_bib49","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0002-9440(10)64131-4","article-title":"Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting","volume":"158","author":"Mesri","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.biopha.2010.03.003_bib50","first-page":"133","article-title":"Expression of the IAPs in multidrug resistant tumor cells","volume":"11","author":"Notarbartolo","year":"2004","journal-title":"Oncol Rep"},{"key":"10.1016\/j.biopha.2010.03.003_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1349-7006.2004.tb03169.x","article-title":"Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients","volume":"95","author":"Nakamura","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.biopha.2010.03.003_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1023\/A:1013123532723","article-title":"Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets","volume":"20","author":"Grossman","year":"2001","journal-title":"Cancer Metastasis Rev"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332210000752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332210000752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:46:11Z","timestamp":1760093171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332210000752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0753332210000752"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2010.03.003","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2010.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}